Greater China News
The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer
NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other malignant tumors, has been approved by the FDA (U.S. Food and Drug Administration).
TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody
HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.
Chinese Drugmakers March Into Africa Seeking New Business Foothold
Chinese pharmaceutical companies are gearing up a foray into Africa with multibillion-yuan investments in local drugmaking facilities, lured by the unmet health-care needs of the world's fastest growing and most underserved continent.
Xi Jinping meets Bill Gates in China, calls him ‘an old friend’
BEIJING, June 16 (Reuters) - Chinese President Xi Jinping called Bill Gates "an old friend" and said he hoped they could cooperate in a way that would benefit both China and the United States, in Xi's first meeting with a foreign entrepreneur in years.
Hong Kong’s VMS Group eyes up to $400m for flagship PE fund
Hong Kong alternative asset management firm VMS Group is targeting $300 million for its flagship private equity fund, with a hard cap of $400 million.
Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited
SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is in advanced discussion with its Company's Chairman and Chief Executive Officer, Mr. Hong Zhida, to acquire Mr Hong's partial stake in Shanghai Bao Pharmaceutical Company Limited.
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca
SHANGHAI, June 16, 2023 /PRNewswire/ -- Cholesgen (Shanghai) Co.Ltd. ('Cholesgen') today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca.
Siemens to spend $2.2 bln to ramp up global production
SINGAPORE/ZURICH, June 15 (Reuters) - Siemens (SIEGn.DE) will spend 2 billion euros ($2.2 billion) on a new global investment plan, the German engineering group said on Thursday, to make its operations more resilient against supply chain disruptions and geopolitical tensions.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress
BEIJING--(BUSINESS WIRE)--Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
